Showing results (1-10 of 42) with videos related to
Sort By:
Pageof 5
Surgical Oncology Clinics of North America|February 24, 2024
Tissue-Agnostic Cancer Therapy ApprovalsMohamed A Gouda, Vivek SubbiahTherapeutic Advances in Medical Oncology|June 26, 2023
Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancersMohamed A Gouda, Vivek SubbiahMed (New York, N.Y.)|November 12, 2022
Exportin(g) precision oncology beyond genomics with XPO1 inhibitionMohamed A Gouda, Vivek SubbiahAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 9, 2023
Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid TumorsMohamed A Gouda, Vivek SubbiahCancer Journal (Sudbury, Mass.)|November 16, 2022
Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision TherapyMohamed A Gouda, Vivek SubbiahSaudi Medical Journal|June 10, 2016
Student research in Arab world. What is the current state?Omar A Aboshady, Mohamed A GoudaMed (New York, N.Y.)|November 11, 2023
Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?Mohamed A Gouda, Kyaw Z TheinSaudi Medical Journal|August 30, 2016
Research output of Arab students. The way forwardYassar Alamri, Omar A Aboshady, Mohamed A GoudaNPJ Precision Oncology|October 9, 2025
Prolonged response to dual immune checkpoint blockade in patients with advanced solid tumors: a case seriesCamila B Xavier, Mohamed A Gouda, Apostolia M TsimberidouCancers|October 16, 2024
Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future DirectionsMohamed A Gouda, Kyaw Z Thein, David S HongPageof 5